Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 100/100

Failure Rate

27.4%

52 terminated/withdrawn out of 190 trials

Success Rate

59.7%

-26.8% vs industry average

Late-Stage Pipeline

4%

8 trials in Phase 3/4

Results Transparency

0%

0 of 77 completed trials have results

Key Signals

24 recruiting35 terminated17 withdrawn

Enrollment Performance

Analytics

Phase 2
69(46.9%)
N/A
36(24.5%)
Phase 1
30(20.4%)
Phase 3
8(5.4%)
Early Phase 1
4(2.7%)
147Total
Phase 2(69)
N/A(36)
Phase 1(30)
Phase 3(8)
+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (190)

Showing 20 of 190 trials
NCT05345847Not ApplicableRecruiting

Steroid Sparing in Immune Related Hepatitis (irH)

Role: lead

NCT06789081Early Phase 1Active Not Recruiting

GPNMB-targeting Chimeric Antigen Receptor T-Cell Therapy (GCAR1) for a Patient With Alveolar Soft Part Sarcoma (CLIC-YYC-GPNMB-02)

Role: lead

NCT06860542Phase 2Recruiting

Inhaled Budesonide for REcurrence Prevention and Adjuvant THerapy in Checkpoint Inhibitor Pneumonitis

Role: lead

NCT04765514Phase 2Recruiting

Chemoradiotherapy Versus Chemotherapy for Elderly and Frail GBM Patients

Role: lead

NCT06790589Phase 2Not Yet Recruiting

COACH - Comparing Two Different Methods to Suppress Thyrotropin in Patients With Advanced Thyroid Cancer

Role: lead

NCT05421416Phase 2Recruiting

Loratadine for the Prevention of G-CSF-related Bone Pain

Role: lead

NCT04990895Not ApplicableTerminated

A Research Study to Collect Patient Reported Outcomes Using Electronic Surveys

Role: lead

NCT07330583Phase 2Not Yet Recruiting

Stereotactic Body Radiation Therapy (SBRT) and Immunotherapy for Oligometastatic Esophageal Cancer

Role: lead

NCT04765241Not ApplicableActive Not Recruiting

mHealth Physical Activity Intervention for Young Cancer Survivors

Role: lead

NCT06001125Phase 2Terminated

Methotrexate for Immune Related Arthritis or Arthralgias (IMPACT 2.1)

Role: lead

NCT04677049Phase 1Suspended

Study of Niacin in Glioblastoma

Role: lead

NCT07291557Phase 2Not Yet Recruiting

PSMA-PET Directed Radiation Therapy for High-Risk Prostate Cancer

Role: lead

NCT02297217Phase 2Recruiting

Chemoradiotherapy for Advanced Esophageal Cancer

Role: lead

NCT05128734Phase 2Not Yet Recruiting

Temozolomide Monotherapy or in Combination With Olaparib in Patients With Triple Negative Breast Cancer (TNBC)

Role: lead

NCT04268199Phase 2Recruiting

A Multicentre, Non-Blinded Study Exploring Self-Administration of Chemotherapy in the Home Environment

Role: lead

NCT06882174Phase 2Not Yet Recruiting

This Study is Comparing Morning vs Random Scheduling of Standard of Care Pembrolizumab Checkpoint Inhibitor Immunotherapy Infusions in Patients With Metastatic Non-small Cell Lung Cancer

Role: lead

NCT05040815Phase 2Recruiting

Inguinal Node Sparing Radiotherapy For Patients With Early Stage Anal Cancer

Role: lead

NCT01876771Phase 2Recruiting

A Trial to Assess the Safety and Effectiveness of Lutetium-177 Octreotate Therapy in Neuroendocrine Tumours

Role: lead

NCT06827886Early Phase 1Completed

GPNMB-targeting Chimeric Antigen Receptor T-Cell Therapy (GCAR1) for a Patient With Alveolar Soft Part Sarcoma

Role: lead

NCT04474925Phase 3Terminated

Pre- Versus Post-operative SRS for Resectable Brain Metastases

Role: lead